scholarly article | Q13442814 |
P356 | DOI | 10.1517/14656561003777026 |
P698 | PubMed publication ID | 20402556 |
P50 | author | G Ralph Corey | Q115862748 |
Martin E Stryjewski | Q115862786 | ||
Esteban C Nannini | Q39392197 | ||
P2860 | cites work | Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period | Q41066970 |
In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model | Q42111513 | ||
In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model | Q42627381 | ||
Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia | Q43153489 | ||
In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. | Q45004641 | ||
Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q46826194 | ||
Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. | Q54120637 | ||
In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. | Q54440265 | ||
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. | Q55067143 | ||
Methicillin-ResistantS. aureusInfections among Patients in the Emergency Department | Q55897489 | ||
Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections | Q24672937 | ||
Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus | Q28362193 | ||
Invasive methicillin-resistant Staphylococcus aureus infections in the United States | Q29616087 | ||
Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study | Q29616607 | ||
Clinical practice. Infection associated with prosthetic joints | Q33771840 | ||
Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains | Q33938055 | ||
TAK-599, a novel N-Phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties | Q33965890 | ||
Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics | Q34012457 | ||
Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target | Q34510488 | ||
Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance | Q34547868 | ||
Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 | ||
Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care | Q36023547 | ||
Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus | Q36482771 | ||
In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae | Q37072096 | ||
Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections | Q39744021 | ||
P433 | issue | 7 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 1197-1206 | |
P577 | publication date | 2010-05-01 | |
P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
P1476 | title | Ceftaroline for complicated skin and skin-structure infections | |
P478 | volume | 11 |
Q57210839 | Ceftaroline Resistance by Clone-Specific Polymorphism in Penicillin-Binding Protein 2a of Methicillin-Resistant Staphylococcus aureus |
Q37809059 | Current medical management of diabetic foot infections |
Q37800939 | Invasive community-associated MRSA infections: epidemiology and antimicrobial management |
Q37942654 | Will new antimicrobials overcome resistance among Gram-negatives? |
Search more.